Cumberland Pharmaceuticals (CPIX) financial statements
Cumberland Pharmaceuticals reported revenue of $45M in fiscal 2025, up 3.4% a year over 9 years.
Net income was -$3M and the operating margin -6.3%, against -4.3% in 2016.
Free cash flow was $5M, and the company returned $263,478 in net buybacks.
The diluted share count fell 9% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Cumberland Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33M | $41M | $29M | $34M | $37M | $36M | $42M | $40M | $38M | $45M |
| Cost of revenue | $6M | $7M | $6M | $7M | $9M | $9M | $9M | $6M | $7M | $7M |
| Gross profit | $27M | $34M | $23M | $27M | $29M | $27M | $33M | $33M | $31M | $38M |
| Research and development | $3M | $4M | $8M | $7M | $6M | $6M | $7M | $6M | $5M | $6M |
| Selling, general and admin | $23M | $31M | $24M | $25M | $25M | $25M | $27M | $29M | $28M | $31M |
| Operating income | -$1M | -$4M | -$11M | -$9M | -$6M | -$8M | -$6M | -$10M | -$6M | -$3M |
| Interest expense | $106,392 | $92,904 | $195,848 | $246,186 | $263,627 | $98,031 | $585,995 | $667,861 | $605,508 | $495,990 |
| Pre-tax income | -$1M | -$4M | -$11M | -$9M | -$7M | -$6M | -$6M | -$6M | -$6M | -$3M |
| Income tax | -$330,924 | $4M | $16,636 | -$79,316 | $55,902 | $34,891 | $68,850 | $45,769 | -$22,669 | $40,256 |
| Net income | -$944,683 | -$8M | -$7M | -$4M | -$3M | -$4M | -$6M | -$6M | -$6M | -$3M |
| EPS (diluted) | -$0.06 | -$0.50 | -$0.45 | -$0.23 | -$0.22 | -$0.24 | -$0.38 | -$0.44 | -$0.46 | -$0.19 |
| Diluted shares | 16M | 16M | 16M | 15M | 15M | 15M | 15M | 14M | 14M | 15M |
| Gross margin | 82.0% | 82.1% | 79.5% | 78.4% | 76.9% | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% |
| Operating margin | -4.3% | -9.9% | -38.1% | -27.0% | -17.0% | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% |
| Net margin | -2.9% | -19.4% | -23.7% | -10.3% | -8.9% | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% |
Balance sheet
Fiscal years, from Cumberland Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $50M | $50M | $36M | $28M | $25M | $27M | $20M | $18M | $18M | $11M |
| Receivables | $7M | $8M | $8M | $8M | $12M | $7M | $13M | $10M | $12M | $17M |
| Inventory | $5M | $7M | $12M | $9M | $11M | $8M | $10M | $5M | $4M | $29,935 |
| Total current assets | $66M | $69M | $59M | $50M | $50M | $46M | $46M | $36M | $36M | $37M |
| Property, plant and equipment | $464,454 | $528,882 | $771,213 | $747,796 | $574,169 | $442,635 | $284,039 | $367,903 | $277,365 | $264,724 |
| Goodwill | — | $0 | $784,000 | $882,000 | $882,000 | $882,000 | $914,000 | $914,000 | $914,000 | $914,000 |
| Total assets | $93M | $93M | $113M | $105M | $96M | $84M | $93M | $82M | $76M | $77M |
| Total current liabilities | $15M | $18M | $28M | $24M | $26M | $19M | $29M | $28M | $32M | $37M |
| Total liabilities | $20M | $29M | $57M | $53M | $50M | $42M | $57M | $53M | $53M | $52M |
| Shareholders' equity | $73M | $64M | $56M | $51M | $47M | $43M | $36M | $30M | $23M | $25M |
| Net debt | -$35M | -$45M | -$28M | -$28M | -$25M | -$27M | -$20M | -$18M | -$13M | -$11M |
Cash flow
Fiscal years, from Cumberland Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $569,478 | -$557,714 | $3M | $3M | $5M | $6M | $8M | $6M | -$612,186 | $5M |
| Capital spending | $130,872 | $275,960 | $455,569 | $246,202 | $140,817 | $103,532 | $102,148 | $281,268 | $66,461 | $97,903 |
| Free cash flow | $438,606 | -$833,674 | $3M | $3M | $5M | $6M | $8M | $6M | -$678,647 | $5M |
| Stock-based compensation | $852,102 | $1M | $1M | $1M | $1M | $741,867 | $447,503 | $365,040 | $301,895 | $408,320 |
| Share buybacks (net) | -$3M | -$4M | -$3M | -$3M | -$2M | -$1M | -$1M | -$740,533 | -$579,049 | -$263,478 |
| Free cash flow margin | 1.3% | -2.0% | 9.1% | 8.2% | 14.1% | 17.3% | 19.9% | 14.7% | -1.8% | 10.9% |
Questions
What was Cumberland Pharmaceuticals's revenue in 2025?
$45M in fiscal 2025, from its 10-K filing.
How much free cash flow does Cumberland Pharmaceuticals generate?
$5M in fiscal 2025 (operating cash flow minus capital spending).
From Cumberland Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.